Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Diabetes in Developing Countries
Literature
1.
Bosi E, Lucotti P, Setola E, Monti L, Piatti PM. Incretin-based therapies in type 2 diabetes: a review of clinical results. Diabetes Res Clin Pract. 2008;82 Suppl 2:102–7.CrossRef
2.
Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab. 2001;281:E155–61.PubMed
3.
Christensen M, Knop FK. Once-weekly GLP-1 agonists: how do they differ from exenatide and liraglutide? Curr Diab Rep. 2010;10:124–32.PubMedCrossRef
4.
Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. for the DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study. Lancet. 2008;372:1240–50.
5.
Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hao Hu H, et al. for the DURATION-1 Study Group. DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss Over 52 Weeks. Diab Care 2010 Mar 9 [Epub ahead of print].
6.
Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, Yan P, et al. for the DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomized trial. Lancet. 2010;376:431–39.
7.
Diamant M, Gaal LV, Stranks S, Northrup J, Cao D, Taylor K, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomized trial. Lancet. 2010;375:2234–43.PubMedCrossRef
8.
9.
Metadata
Title
Once-weekly exenatide in type 2 diabetes
Authors
Dinesh M. Parmar
Shilpa P. Jadav
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
International Journal of Diabetes in Developing Countries / Issue 2/2011
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-011-0018-2

Other articles of this Issue 2/2011

International Journal of Diabetes in Developing Countries 2/2011 Go to the issue

Original Article

Insulin-like growth factor-1 in correlation with bone mineral density among Egyptian adolescents with type 1 diabetes mellitus

Original Article

Efficacy of ethanolic extract of ginger on kidney lipid metabolic profiles in diabetic rats

Editorial

Will the epidemic of diabetes in India subside?

Original Article

Effect of human umbilical cord blood CD34+ progenitor cells transplantation in diabetic mice

Original Article

Islet cell autoantibodies in patients younger than 20 years of age with recently diagnosed diabetes in Northwest of Iran

Review Article

Computerization of data in diabetes centers

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits